SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Mifepristone Linepharma 200 mg tablet

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 200 mg of mifepristone.
For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Tablet.
White to off-white, round tablet, diameter 11mm, with MF debossed on one side of the tablet.

4 CLINICAL PARTICULARS

For termination of pregnancy, Mifepristone Linepharma 200mg tablet and prostaglandins can only be prescribed and administered in accordance with countries national laws and regulations.

4.1 Therapeutic indications

Medical termination of a developing intra-uterine pregnancy in sequential combination with a prostaglandin analogue up to 63 days of amenorrhea.

4.2 Posology and method of administration

Medical termination of developing intra-uterine pregnancy up to 63 days of amenorrhea. The method of administration is 200 mg of mifepristone in a single oral dose, followed 36 to 48 hours later by the administration of the prostaglandin analogue gemeprost 1 mg per vaginam.

The dose of 200 mg should not be exceeded.

Paediatric population
No data are available for women under 18 years.
4.3 Contraindications

This product should never be prescribed in the following situations:

- known hypersensitivity to the active substance or to any of the excipients;
- chronic adrenal failure;
- severe disease (e.g. asthma uncontrolled by therapy);
- inherited porphyria

**in the indication: medical termination of developing pregnancy**

- pregnancy not confirmed by an ultrasound or biological test;
- pregnancy beyond 63 days of amenorrhea;
- suspected ectopic pregnancy;
- contraindication to the prostaglandin analogue selected.

4.4 Special warnings and precautions for use

- **Warnings:**

  In the absence of specific studies, Mifepristone Linepharma is not recommended in patients with:

  - Renal failure,
  - Hepatic failure
  - Malnutrition

**Medical termination of developing intra-uterine pregnancy**

This method requires the involvement of the woman who should be informed of the requirements of the method:
- The necessity to combine treatment with prostaglandin to be administered at a second visit.

- The need for a follow up visit (3rd visit) within 14 to 21 days after intake of Mifepristone Linepharma in order to check for complete expulsion.

- The non-negligible risk of failure (see section 5.1) of the method which may require termination by another method.

In the case of a pregnancy occurring with an intra-uterine device in situ, this device must be removed before administration of Mifepristone Linepharma.

The expulsion may take place before prostaglandin administration (in about 3% of cases). This does not preclude the control visit in order to check for the complete expulsion and the uterine vacuity.

The risks related to the method must be taken into account and explained to the woman:

- Failures

  The non-negligible risk of failure, which occurs in up to 11.7% of the cases, makes the control visit mandatory in order to check that the expulsion is completed.

- Bleeding

  The patient must be informed of the occurrence of prolonged vaginal bleeding (an average of 10 to 16 days after Mifepristone Linepharma intake) which may be heavy. Bleeding occurs in almost all cases and is not in any way proof of complete expulsion. (see section 4.8).

  The patient should be informed not to travel far away from the prescribing centre as long as complete expulsion has not been recorded. She will receive precise instructions as to whom she should contact and where to go, in the event of any problems emerging, particularly in the case of very heavy vaginal bleeding.

  A follow-up visit must take place within a period of 14 to 21 days after administration of mifepristone to verify by the appropriate means (clinical examination, ultrasound scan, and beta-hCG measurement) that expulsion has been completed and that vaginal bleeding has stopped. In case of persistent
bleeding (even light) beyond the control visit, its disappearance should be checked within a few days.

If an ongoing pregnancy is suspected, a further ultrasound scan may be required to evaluate its viability.

Persistence of vaginal bleeding at this point could signify incomplete abortion, or an unnoticed extra-uterine pregnancy, and appropriate treatment should be considered.

In the event of an ongoing pregnancy diagnosed after the control visit, termination by another method will be proposed to the woman.

Since heavy bleeding requiring haemostatic curettage occurs in up to 5% of the cases during the medical method of pregnancy termination, special care should be given to patients with haemostatic disorders with hypocoagulability, or with anaemia. The decision to use the medical or the surgical method should be decided with specialised consultants according to the type of haemostatic disorder and the level of anaemia.

Infection

Very rare cases of fatal toxic shock caused by Clostridium sordellii endometritis presenting without fever or other obvious symptoms of infection, have been reported after medical abortion with the use of 200 mg mifepristone followed by non authorised vaginal administration of misoprostol tablets for oral use. Clinicians should be aware of this potentially fatal complication.

In all instances

The use of Mifepristone Linepharma requires rhesus determination and hence the prevention of rhesus allo-immunisation as well as other general measures taken usually during any termination of pregnancy.

During clinical trials, pregnancies occurred between embryo expulsion and the resumption of menses.
To avoid potential exposure of a subsequent pregnancy to mifepristone, it is recommended that conception be avoided during the next menstrual cycle. Reliable contraceptive precautions should therefore commence as early as possible after mifepristone administration.

In case of suspected acute adrenal failure, dexamethasone administration is recommended. 1 mg of dexamethasone antagonises a dose of 400 mg of mifepristone.

Due to the antiglucocorticoid activity of mifepristone, the efficacy of long-term corticosteroid therapy, including inhaled corticosteroids in asthmatic patients, may be decreased during the 3 to 4 days following intake of Mifepristone Linepharma. Therapy should be adjusted.

A decrease of the efficacy of the method can theoretically occur due to the antiprostaglandin properties of non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin (acetyl salicylic acid). Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of medical termination of pregnancy.

**For the sequential use of Mifepristone Linepharma-Prostaglandin**

The precautions related to the prostaglandin used should be followed where relevant

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

On the basis of this drug's metabolism by CYP3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). Furthermore, rifampicin, dexamethasone, St. John's Wort and certain anticonvulsants (phenytin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).

Based on in vitro inhibition information, co-administration of mifepristone may lead to an increase in serum levels of drugs that are CYP3A4 substrates. Due to the slow elimination of mifepristone from the body, such interaction may be observed for a prolonged period after its administration. Therefore, caution should be exercised when mifepristone is administered with drugs that are CYP3A4 substrates and have narrow therapeutic range, including some agents used during general anesthesia.
4.6 **Fertility, pregnancy and lactation**

**Pregnancy**

In animals (see section 5.3), the abortifacient effect of mifepristone precludes the proper assessment of any teratogenic effect of the molecule.

With sub abortive doses, isolated cases of malformations observed in rabbits, but not in rats or mice were too few to be considered significant, or attributable to mifepristone.

In humans, the few reported cases of malformations do not allow a causality assessment for mifepristone alone or associated to prostaglandin. Therefore, data is too limited to determine whether the molecule is a human teratogen (see section 4.8).

Consequently:

- Patient should be informed that due to the risk of failure of the medical method of pregnancy termination and to the unknown risk to the fetus, the control visit is mandatory (see section 4.4).
- Should a failure of the method be diagnosed at the control visit (viable ongoing pregnancy), and should the patient still agree, pregnancy termination should be completed by another method.

Should the patient wish to continue with her pregnancy, the available data is too limited to justify a systematic termination of an exposed pregnancy. In that event, careful ultra-sonographic monitoring of the pregnancy should be carried out.

**Lactation**

Mifepristone is a lipophilic compound and may theoretically be excreted in the mother's breast milk. However, limited data is available. Consequently, Mifepristone Linepharma use should be avoided during breast-feeding.

**Fertility**

During clinical trials, pregnancies occurred between embryo expulsion and the resumption of menses. To avoid potential exposure of a subsequent pregnancy to mifepristone, it is recommended that conception be avoided during the next menstrual cycle. Reliable contraceptive precautions should therefore commence as early as possible after Mifepristone Linepharma administration.
4.7 Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been performed.
4.8 Undesirable effects

The adverse events reported with mifepristone, classified according to frequency and system organ class, are summarized in the following table:

<table>
<thead>
<tr>
<th>MedDRA</th>
<th>Adverse events (frequency)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>System Organ Class</td>
<td>Very common &gt; 1/10</td>
<td>Common &gt; 1/100 to &lt; 1/10</td>
<td>Uncommon &gt; 1/1000 to &lt; 1/100</td>
<td>Rare &gt; 1/10000 to &lt; 1/1000 and very rare (&lt; 1/10000)*</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Nausea Vomiting Diarrhea Dizziness Gastric discomfort Abdominal pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>Vaginal bleeding Uterine spasm Prolonged post-abortion bleeding Spotting Severe hemorrhage Endometritis Breast tenderness Heavy bleeding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Fatigue Chill / fever</td>
<td>Fainting</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gastric bleeding
Epilepsy
Neurogenic tinnitus
Bilateral adnexal mass
Intrauterine adhesion Ovarian cyst rupture Breast abscess Hematosalpinx Uterine rupture
Anaphylaxis
Periorbital edema
<table>
<thead>
<tr>
<th>MedDRA</th>
<th>Adverse events (frequency)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>System Organ Class</strong></td>
<td></td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Infection</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hot flush</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Induced Adam-Stokes syndrome</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Bronchospasm</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Skin rash / pruritus</td>
</tr>
<tr>
<td>Pregnancy, puerperium and perinatal conditions</td>
<td>Hydatiform mole</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Abnormal liver function tests</td>
</tr>
</tbody>
</table>

**Very common**

- Greater than or equal to 1/10

**Common**

- Greater than 1/100 to less than 1/10

**Uncommon**

- Greater than 1/1000 to less than 1/100

**Rare**

- Greater than 1/10000 to less than 1/1000 and very rare
- Less than 1/10000

---

**Infections and infestations**

- Infection

**Vascular disorders**

- Hot flush

**Cardiac disorders**

- Myocardial infarction
- Induced Adam-Stokes syndrome

**Respiratory, thoracic and mediastinal disorders**

- Bronchospasm
- Induced bronchial asthma

**Skin and subcutaneous tissue disorders**

- Skin rash / pruritus
- Urticarial reaction
- Toxic epidermal necrolysis

**Pregnancy, puerperium and perinatal conditions**

- Hydatiform mole
- Ectopic pregnancy
- Amniotic band syndrome
- Gestational trophoblastic tumor
- Uteroplacental apoplexy

**Hepatobiliary disorders**

- Abnormal liver function tests
- Hepatic failure
- Hepatorenal failure
<table>
<thead>
<tr>
<th>MedDRA</th>
<th>Adverse events (frequency)</th>
</tr>
</thead>
<tbody>
<tr>
<td>System Organ Class</td>
<td>Very common &gt; 1/10</td>
</tr>
<tr>
<td></td>
<td>Common &gt; 1/100 to &lt; 1/10</td>
</tr>
<tr>
<td></td>
<td>Uncommon &gt; 1/1000 to &lt; 1/100</td>
</tr>
<tr>
<td></td>
<td>Rare &gt; 1/10000 to &lt; 1/1000 and very rare (&lt; 1/10000)*</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Thrombotic thrombocytopenic purpura Thrombocytopenia Induced systemic lupus erythematous</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Neoplasms benign, malignant and unspecified</td>
<td>Elevated alpha-feto protein Elevated carcinoembryogenic antigen</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Limb spasm</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Ophtalmoplegia</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Mania</td>
</tr>
</tbody>
</table>

* Including occasional case reports

- Bleeding is an almost constant part of the procedure, whatever the prostaglandin use, and at any pregnancy term although it is usually more abundant when pregnancy age increases. It can occur after mifepristone alone. When heavy, it often reflects incomplete abortion leading to a surgical procedure in approximately 5 percent of the cases. It can necessitate a blood transfusion in 0.5 to 1 percent of the cases.
4.9 Overdose

No case of overdose has been reported.
In the event of massive ingestion signs of adrenal failure might occur. Signs of acute intoxication may require specialist treatment including the administration of dexamethasone.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other Sex Hormone and Modulator of the Reproductive function/ Antiprogestogen. ATC code: GO3XB01

Mifepristone is a synthetic steroid with an antiprogestational action as a result of competition with progesterone at the progesterone receptors.

At doses ranging from 3 to 10mg/kg orally, it inhibits the action of endogenous or exogenous progesterone in different animal species (rat, mouse, rabbit and monkey). This action is manifested in the form of pregnancy termination in rodents.

In patient at doses of greater than or equal to 1mg/kg, mifepristone antagonises the endometrial and myometrial effects of progesterone. During pregnancy it sensitises the myometrium to the contraction inducing action of prostaglandins. During the first trimester, pre-treatment with mifepristone allows the dilatation and opening of the cervix uteri. While clinical data have demonstrated that mifepristone facilitates dilatation of the cervix, no data is available to indicate that this results in a lowering of the rate of early or late complications to the dilatation procedure.

In the event of an early termination of pregnancy, the combination of a prostaglandin analogue used in a sequential regimen after mifepristone leads to an increase in the success rate and accelerates the expulsion of the conceptus.

In clinical trials, according to the prostaglandin used and the time of application, the results vary slightly.
When 1 mg vaginal gemeprost following 200 mg mifepristone is used, the efficacy rate is almost constant until 63 DA: 95.1 to 97.6% before 50 DA, 95.7 to 97.1 % from 50 to 56 DA, 90.0 to 97.6% from 57 to 63 DA.

Failures are due to either incomplete abortion or to persisting pregnancy: in practical terms, whatever their nature, failure necessitate a surgical procedure (vacuum aspiration or dilatation and curettage).

Mifepristone binds to the glucocorticoid receptor. In animals at doses of 10 to 25 mg/kg it inhibits the action of dexamethasone. In man the antiglucocorticoid action is manifested at a dose equal to or greater than 4.5 mg/kg by a compensatory elevation of ACTH and cortisol. Glucocorticoid bioactivity (GBA) may be depressed for several days following a single administration of 200 mg mifepristone for termination of pregnancy. The clinical implications of this are unclear, however vomiting and nausea may be increased in susceptible women.

Mifepristone has a weak anti-androgenic action which only appears in animals during prolonged administration of very high doses

5.2 Pharmacokinetic properties

After oral administration of a single dose of 200 mg mifepristone is rapidly absorbed. The peak concentration of 2.7 mg/l is reached after 0.75 hours (mean of 49 subjects). The half life of mifepristone is 38.3 hours.

Mifepristone shows non-linear pharmacokinetics. Following the distribution phase the elimination is at first slow, with a half-life of approx. 12 to 72 hours, and then the concentration is more rapidly reduced with a half-life of 18 hours. With radio-receptor analysis, the final half-life is shown to be up to 90 hours, including all mifepristone metabolites that can bind to progesterone receptors.

After administration of low doses of mifepristone (20 mg orally or intravenously), the absolute bioavailability is 69%.

In plasma mifepristone is 98% bound to plasma proteins: albumin and principally alpha-1-acid glycoprotein (AAG), to which binding is saturable. Due to this specific binding, volume of distribution and plasma clearance of mifepristone are inversely proportional to the plasma concentration of AAG.

N mono- and di-demethylation and terminal hydroxylation of the 17-propynyl chain are primary metabolic pathways of hepatic oxidative metabolism. Metabolites are
detectable in plasma 1 hour after ingestion of mifepristone. The binding affinity of the metabolites to progesterone receptors is about 10 to 20% of that of mifepristone and it is not known whether they contribute to the pharmacological effects of mifepristone.

*In vitro* CYP3A4 appears as the isoenzyme primarily responsible for mifepristone demethylation and hydroxylation in human liver microsomes. CYP3A4 substrates progesterone and midazolam inhibited metabolite formation by up to 77%. Other isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1) had apparently no action on mifepristone metabolism.

After administration of 600 mg radiolabeled mifepristone, 10% of the total radioactivity was recovered in urine and 90% in faeces.

### 5.3 Preclinical safety data

In toxicological studies in rats and monkeys up to a duration of 6 months, mifepristone produced effects related to its antihormonal (antiprogesterone, antiglucocorticoid and antiandrogenic) activity.

In reproduction toxicology studies, mifepristone acts as a potent abortifacient. No teratogenic effect of mifepristone was observed in rats and mice surviving foetal exposure. In rabbits surviving foetal exposure, however, isolated cases of severe abnormalities occurred (cranial vault, brain and spinal cord). The number of foetal anomalies was not statistically significant and no dose-effect was observed. In monkeys, the number of foetuses surviving the abortifacient action of mifepristone was insufficient for a conclusive assessment.

**Environmental Risk Assessment (ERA)**

The consumption of mifepristone is unlikely to represent a risk for the environment following its prescribed indications.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Maize starch,

Povidone,

Cellulose microcrystalline,

Silica colloidal anhydrous
Magnesium stearate.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Keep it in the outer carton in order to protect from light.

6.5 Nature and contents of container

PVC/PVDC/Aluminum blister of 1 tablet.
Pack sizes with 1 tablet and 30 tablets (as hospital pack).
Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Linepharma France
8 MARKETING AUTHORISATION NUMBER(S)
PL 40060/0001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORITY
08/10/2012

10 DATE OF REVISION OF THE TEXT
07/11/2012